NAM
ANIP icon

Nexpoint Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Nexpoint Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,100
Closed -$438K – 219
2019
Q4 		$438K Hold
7,100
– – 0.03% 207
2019
Q3 		$517K Buy
+7,100
New +$531K 0.03% 246

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nexpoint Asset Management's ANIP Position: Q1 2020 in Review

Nexpoint Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2020, closing a stake of 7,100 shares — an estimated $438K sold.

Nexpoint Asset Management first reported a position in ANIP in Q3 2019 and held it in 2 quarters. The position peaked at $517K in Q3 2019. 140 funds tracked by Wall St. Rank hold ANIP as of Q1 2020.

  • Nexpoint Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Nexpoint Asset Management sold 7,100 ANI Pharmaceuticals shares in Q1 2020, an estimated $438K.
  • Nexpoint Asset Management first reported a position in ANI Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Nexpoint Asset Management's ANI Pharmaceuticals position peaked at $517K in Q3 2019.
  • 140 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2020.

Based on Nexpoint Asset Management's 13F filing for Q1 2020, filed 15 May 2020.